PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143342
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143342
Messenger Ribonucleic Acid (mRNA) Capping Enzyme market size was valued at US$ 1,063.4 Million in 2025, expanding at a CAGR of 15.1% from 2026 to 2033.
The mRNA capping enzyme is a protein complex that is involved in the addition of a 7-methylguanosine cap to the 5' end of the newly formed mRNA transcript for the stability of the RNA molecule, RNA export from the nucleus, and the RNA translation process. The structure of the enzyme that acts as a capping enzyme contains three active centers of protein enzymes, which can function either independently or as a part of the RNA polymerase II complex. These active centers include the capping enzyme, which acts as RNA triphosphatase and removes terminal phosphates from the newly synthesized mRNA transcripts; the capping enzyme, which acts as guanylyl transferase and attaches the GMP from GTP to the 5' diphosphate of the mRNA; and the capping enzyme, which acts as N7 methyl transferase. Thus, mRNA capping enzymes play a pivotal role in ensuring proper mRNA maturation and functional gene expression.
Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market- Market Dynamics
Increasing Use Of Personalized Medicine To Boost Market Expansion
Increasing adoption of personalized medicine in IVF is driving Messenger Ribonucleic Acid (mRNA) Capping Enzyme market because it helps in profiling the embryos in a particular way using the genetic constitution of the embryos, helps in the selection of embryos, makes the decision-making process with regard to reproduction easier, and also helps in risk identification related to genetic abnormalities. For instance, in February 2026, according to the Brazilian Registry of Clinical Trials (Gov), there is growing use of personalized medicine because these are providing excellent results and outcomes in refractory hematologic malignancies where CAR-T cells are genetically modified T-lymphocytes against the tumor antigen. The country is working towards building its own capacity and expertise in research, clinics, and regulations so that it can provide patients with such advanced personalized treatments in the future.
As per the Brazil Registry of Clinical Trials, there are a total of 18,826 clinical trials, including 9,632 active registrations of clinical trials, 5,192 recruiting clinical trials, 89 ongoing analysis trials, and 6,240 drafted clinical trials. This trend is expected to accelerate personalized embryo selection and strengthen precision in IVF treatment strategies.
The Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme market is segmented on the basis of Product Type, Application, End User, and Region.
In the Messenger Ribonucleic Acid (mRNA) Capping Enzyme market, recombinant Messenger Ribonucleic Acid (mRNA) capping enzymes hold a prominent share due to the extensive use of recombinant enzymes like Vaccinia Capping Enzyme (VCE) in artificial mRNA studies and commercialization, especially for 5' mRNA capping purposes. In March 2026, Roche AG introduced its Vaccinia Capping System, which includes recombinant mRNA guanylyltransferase and 2'O-methyltransferase enzymes. The Vaccinia Capping System provides capping, which is of GMP quality and has no animal origin. This move is anticipated to increase the use of recombinant enzymes in mRNA production.
Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market- Geographical Insights
North America is among the most affected regions because of being heavily reliant on imported reagents. It may pose some challenges in terms of supply chains and the difficulties in procurement. For instance, in November 2025, according to U.S. Customs and Border Protection (Gov.), all biological materials imported into the USA, including genetic materials, enzymes, proteins, peptides, diagnostic specimens, cultured cells, antibodies, and other research materials, have to meet the requirements of import documentation, labeling, packaging, declaration, and inspection. If the commercial value of biological materials is higher than $2,500, it will require the formal customs entry process (bonding and duties/taxes/fees).
In case the value is lower than $800, an importer can use the Entry Type 86 electronic filing method if Partner Government Agency (PGA) participation is needed. Also, there are seven categories of biological materials provided by the CBP, which include cultured cells/tissues, diagnostic specimens, genetic materials, genetically modified organisms, human/veterinary products, infectious substances, and microorganisms. This regulatory complexity can further strain supply chains and complicate timely access to specialized reagents.
Asia-Pacific is anticipated to be a growing region in the Messenger Ribonucleic Acid (mRNA) Capping Enzyme market due to increased research activities and biotechnological advancements. For instance, in April 2025, according to the Mercator Institute for China Studies (org), the National Medical Products Administration (NMPA) of China had approved a total of 76 new drugs. This marked a 53% increase in the number of new medicines, with 85% of those having been invented by the companies from China. In the first six months of 2025, the number of vaccinations administered to protect people from novel coronavirus disease was 85 million. One-third of all the multi-regional clinical trials conducted globally were taking place in the Asia-Pacific region. The major pharmaceutical companies spent $3.15 billion in Chinese molecules. This growth is further supported by expanding biotechnology investments and mRNA research capabilities across the region.
The competitive landscape of the Messenger Ribonucleic Acid (mRNA) Capping Enzyme market is evolving as key players such as TriLink Biotechnologies, Thermo Fisher Scientific, New England Biolabs, Jena Bioscience, and Aldevron produce next-generation cap analogs used during co-transcription. These analogs guarantee the maximum stability and translation efficiency. In February 2025, TriLink BioTechnologies entered into the non-exclusive license and supply agreement with Aldevron, giving access to the company's mRNA capping technology-CleanCap(R). This collaboration between the two firms looks like it will be highly significant for the future advancement of the mRNA capping technology.
In May 2025, TriLink BioTechnologies signed a memorandum of understanding with the International Vaccine Institute for collaborating in the development of mRNA vaccines through knowledge exchange and joint scientific initiatives using mRNA technology.